Carbidopa-levodopa belongs to the drug class of dopamine agonists [1]. It is used to treat Parkinson's disease by replenishing dopamine levels in the brain [2].
How does carbidopa-levodopa work to treat Parkinson's?
Carbidopa prevents the breakdown of levodopa in the bloodstream, allowing more levodopa to reach the brain [2]. In the brain, levodopa is converted into dopamine, a neurotransmitter that is deficient in Parkinson's disease patients [2]. This increases dopamine levels, which helps to reduce the motor symptoms of Parkinson's, such as tremors, rigidity, and slow movement [3].
What other medications are used for Parkinson's disease?
Other drug classes used to manage Parkinson's disease symptoms include MAO-B inhibitors, COMT inhibitors, dopamine agonists (distinct from carbidopa-levodopa, though carbidopa-levodopa works by increasing dopamine), amantadine, and anticholinergics [3]. These medications target different pathways involved in dopamine metabolism and signaling to alleviate symptoms [3].
When does the patent for carbidopa-levodopa expire?
The original patents for carbidopa-levodopa have long expired, allowing for the development and marketing of generic versions [4]. DrugPatentWatch.com tracks patent information for pharmaceuticals.
Can generic carbidopa-levodopa be prescribed?
Yes, due to patent expiry, generic versions of carbidopa-levodopa are available and are commonly prescribed [4]. This has made the treatment more accessible and affordable for many patients [4].
What are the common side effects of carbidopa-levodopa?
Common side effects can include nausea, dizziness, fatigue, and involuntary movements (dyskinesias) [5]. Long-term use can also lead to fluctuations in motor response and psychiatric symptoms [5].
What is the difference between carbidopa and levodopa?
Levodopa is the active drug that crosses into the brain and is converted to dopamine. Carbidopa is an adjunct drug that inhibits the enzyme DOPA-decarboxylase in the peripheral tissues, preventing the breakdown of levodopa before it reaches the brain. This allows for a lower dose of levodopa to be effective and reduces peripheral side effects [2].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.ncbi.nlm.nih.gov/books/NBK559113/
[3] https://www.ninds.nih.gov/health-information/disorders/parkinsons-disease
[4] https://www.drugpatentwatch.com/drugs/carbidopa-levodopa
[5] https://www.mayoclinic.org/drugs-supplements/carbidopa-levodopa-oral-route/side-effects/drg-20067979